Clinical trial · Interventional
Evaluation of Platelet Aggregability in Patients with Non-small Cell Lung Carcinomas
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Cancer patients are at greater risk of experiencing events thrombotic, arterial or venous, during the course of the disease. Specifically in lung cancer, patients are seven times more prone to developing venous thrombosis, when compared to general population. Platelets influence cancer progression and Tumor microenvironment facilitates platelet activation. Therefore, the main objective of this project is to evaluate platelet aggregation analyzed by aggregometry optics with the use of AggRAM® equipment in patients diagnosed recent non-small cell lung carcinomas, prior to any oncological treatment. Among the secondary objectives, it stands out analyze the primary objective using the PPAnalysis® method (method in developed by our group in partnership with the University of Readings (UK), Plateletworks® and Chrono-log. This is a case-control study, with groups differentiated by the presence or absence of malignant lung neoplasia and matched by age, sex and presence or absence of smoking in the previous 6 months to inclusion. Patients diagnosed with non-cell lung carcinoma Small children without prior treatment will be candidates for participation in the study. It is expected that at the end important aspects related to aggregation platelet disease are better characterized in this neoplasm, the most important cause of death from cancer in the world, and therapeutic strategies to improvement in morbidity and mortality in the disease can be developed.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Assessment of Platelet Aggregability in Patients Patients with Non-small Cell Lung Carcinoma | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Clopidogrel | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- control (group 1)
- description
- patients without NSCLC and matched by age, sex and presence or absence of smoking in the 6 months before inclusion
- interventionNames
- Drug: Clopidogrel
- type
- ACTIVE_COMPARATOR
- label
- case (group 2)
- description
- patients with NSCLC and matched by age, sex and presence or absence of smoking in the 6 months prior to inclusion
- interventionNames
- Drug: Clopidogrel
Primary outcomes (1)
- measure
- Platelet Aggregation analyzed by optical aggregometry-ADP (AggRAM™- Helena Laboratories)
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients \> 18 years old; * Confirmed diagnosis of non-small cell lung carcinoma in the case group; absence of history of any neoplasia for control group * Agreement to sign the Free and Informed Consent Form Exclusion Criteria: * Anticoagulation in the last 30 days; * Use of any antiplatelet agent in the last 30 days; * Use of any non-steroidal anti-inflammatory drugs in the last 30 days; * Known platelet dysfunction or platelets \<100,000/mm3 or \>450,000/mm3; * Creatinine clearance by MDRD \<30 ml/min/1.73 m2 * Eastern Cooperative Oncology Group Performance Status Scale (ECOG) \>2 * Known coagulation disorder; * Hematocrit less than 34% or greater than 55%
References
Publications (13)
- BACKGROUNDFuentes HE, Oramas DM, Paz LH, Casanegra AI, Mansfield AS, Tafur AJ. Meta-analysis on anticoagulation and prevention of thrombosis and mortality among patients with lung cancer. Thromb Res. 2017 Jun;154:28-34. doi: 10.1016/j.thromres.2017.03.024. Epub 2017 Apr 1. PMID 28402864
- BACKGROUNDMutlu H, Artis TA, Erden A, Akca Z. Alteration in mean platelet volume and platicrit values in patients with cancer that developed thrombosis. Clin Appl Thromb Hemost. 2013 Jun;19(3):331-3. doi: 10.1177/1076029611433644. Epub 2012 Feb 16. PMID 22345488
- BACKGROUNDZacharski LR, Henderson WG, Rickles FR, Forman WB, Cornell CJ Jr, Forcier RJ, Edwards RL, Headley E, Kim SH, O'Donnell JF, et al. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75. Cancer. 1984 May 15;53(10):2046-52. doi: 10.1002/1097-0142(19840515)53:103.0.co;2-f. PMID 6322957
- BACKGROUNDEk L, Gezelius E, Bergman B, Bendahl PO, Anderson H, Sundberg J, Wallberg M, Falkmer U, Verma S, Belting M; Swedish Lung Cancer Study Group (SLUSG). Randomized phase III trial of low-molecular-weight heparin enoxaparin in addition to standard treatment in small-cell lung cancer: the RASTEN trial. Ann Oncol. 2018 Feb 1;29(2):398-404. doi: 10.1093/annonc/mdx716. PMID 29106448
- BACKGROUNDMacbeth F, Noble S, Evans J, Ahmed S, Cohen D, Hood K, Knoyle D, Linnane S, Longo M, Moore B, Woll PJ, Appel W, Dickson J, Ferry D, Brammer C, Griffiths G. Randomized Phase III Trial of Standard Therapy Plus Low Molecular Weight Heparin in Patients With Lung Cancer: FRAGMATIC Trial. J Clin Oncol. 2016 Feb 10;34(5):488-94. doi: 10.1200/JCO.2015.64.0268. Epub 2015 Dec 23. PMID 26700124
- BACKGROUNDAltinbas M, Coskun HS, Er O, Ozkan M, Eser B, Unal A, Cetin M, Soyuer S. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost. 2004 Aug;2(8):1266-71. doi: 10.1111/j.1538-7836.2004.00871.x.